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Abstract
Background:  The etiology and pathophysiology of chronic fatigue syndrome (CFS) remain
inchoate. Attempts to elucidate the pathophysiology must consider sleep physiology, as
unrefreshing sleep is the most commonly reported of the 8 case-defining symptoms of CFS.
Although published studies have consistently reported inefficient sleep and documented a variable
occurrence of previously undiagnosed primary sleep disorders, they have not identified
characteristic disturbances in sleep architecture or a distinctive pattern of polysomnographic
abnormalities associated with CFS.
Methods: This study recruited CFS cases and non-fatigued controls from a population based study
of CFS in Wichita, Kansas. Participants spent two nights in the research unit of a local hospital and
underwent overnight polysomnographic and daytime multiple sleep latency testing in order to
characterize sleep architecture.
Results:  Approximately 18% of persons with CFS and 7% of asymptomatic controls were
diagnosed with severe primary sleep disorders and were excluded from further analysis. These
rates were not significantly different. Persons with CFS had a significantly higher mean frequency of
obstructive apnea per hour (p = .003); however, the difference was not clinically meaningful. Other
characteristics of sleep architecture did not differ between persons with CFS and controls.
Conclusion: Although disordered breathing during sleep may be associated with CFS, this study
generally did not provide evidence that altered sleep architecture is a critical factor in CFS. Future
studies should further scrutinize the relationship between subjective sleep quality relative to
objective polysomnographic measures.
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Background
Chronic fatigue syndrome (CFS) presents a diagnostic and
management challenge. A case of CFS is defined by: 1)
clinically unexplained, persistent or relapsing fatigue of at
least 6 months' duration that is not the result of ongoing
exertion, is not substantially alleviated by rest, and results
in substantial reduction in previous levels of occupa-
tional, educational, social, or personal activities, and; 2)
concurrent occurrence of at least 4 accompanying symp-
toms (unusual post-exertional malaise, unrefreshing
sleep, significant impairment in memory/concentration,
headache, muscle pain, joint pain, sore throat and tender
lymph nodes) [1]. No characteristic physical signs or diag-
nostic laboratory abnormalities herald CFS. Thus, diagno-
sis depends on evaluation of self-reported symptoms and
ruling out medical or psychiatric conditions that could
cause the illness. Similarly, the pathophysiology of CFS
remains inchoate and as yet there is no definitive treat-
ment; rather, therapy (both pharmacologic and nonphar-
macologic) is directed toward relieving symptoms and
improving function [2].
Attempts to elucidate the pathophysiology of CFS must
consider sleep physiology. Unrefreshing sleep is the most
common of the 8 CFS-defining symptoms, reported by 88
to 95% of cases identified in population studies [3,4] and
70 to 80% of patients in clinic-based studies [5]. Most of
the postulated etiologies of CFS (e.g., infection, immune
and hormone perturbations) affect sleep; and, conversely,
primary sleep disorders, sleep deprivation and experimen-
tal disruption of sleep produce many of the features of
CFS (e.g., fatigue, impaired cognition, joint pain and stiff-
ness) [7-10]. Indeed, untreated primary sleep disorders,
such as sleep apnea and narcolepsy, preclude diagnosis of
CFS [1,11].
The aforementioned issues raise a central question. Does
CFS account for the accompanying sleep disturbances or
does an underlying sleep abnormality result in or contrib-
ute to CFS? Studies of sleep in persons identified with CFS
through tertiary care clinics have not contributed substan-
tially to answering this question [6,12-16]. Although pre-
vious studies have consistently reported inefficient sleep
and documented a varying occurrence of previously undi-
agnosed primary sleep disorders, they have not identified
characteristic disturbances in sleep architecture or a dis-
tinctive pattern of polysomnographic abnormalities asso-
ciated with CFS. As with many studies of CFS, published
evaluations of sleep pathology have not uniformly
applied the case definition of CFS and often lack appropri-
ate comparison groups. People with CFS use a number of
prescription and over the counter medications that affect
sleep [17]; yet most studies do not mention whether or
not medications have been considered. Finally, we are
aware of no published studies of CFS that have utilized
multiple-night polysomnography, nor are we aware of
any published studies that address sleep pathology in a
population-based sample of persons with CFS. Because an
overwhelming majority of persons with CFS remain undi-
agnosed [4,18], results of studies on CFS patients identi-
fied through physician practices may not be generalizable.
The objective of this study was to describe clinical and
polysomnographic sleep characteristics of persons with
CFS identified from the general population of Wichita,
Kansas [4], compared to non-fatigued controls matched
for sex, race, age, and body mass index who were ran-
domly selected from the same population. All study par-
ticipants were admitted to a research ward in Wichita for
2 days [19]. They underwent a complete physical and psy-
chiatric evaluation, their medications were reviewed and
they completed 2-overnight polysomnographic studies
and a multiple sleep latency (MSLT) evaluation. This
report evaluates associations of sleep disorders and varia-
tions in sleep architecture with CFS.
Methods
Participants
This study adhered to U.S. Department of Health and
Human Services human experimentation guidelines and
received Institutional Review Board approval from the
CDC and collaborating institutions. All participants gave
informed consent.
Between January and July 2003, we conducted a 2-day in-
hospital study of adults identified with CFS from the gen-
eral population of Wichita [19]. The in-hospital study
enrolled people who had participated in the 1997
through 2000 Wichita Population-Based CFS Surveillance
Study  [4]. Participants in the in-hospital study were
fatigued adults with medically/psychiatrically unex-
plained chronic fatigue identified during the surveillance
study. Fifty-eight had been diagnosed at least once with
CFS and 59 had unexplained chronic fatigue that was not
CFS. Controls were randomly selected from the cohort
who participated throughout surveillance, who did not
have medical or psychiatric exclusions, and who had not
reported fatigue of at least 1-month duration; they were
matched to CFS cases on sex, age, race/ethnicity, and body
mass index. Upon admission to this study, subjects were
reevaluated for CFS symptoms and exclusionary medical
and psychiatric conditions (discussed below). The 43
who, at the time of the in-hospital study, met 1994 criteria
for CFS (discussed below) comprise the cases in this
report. Controls are 43 individuals who had never
reported fatigue during the surveillance study, who were
not fatigued at the time of this in-hospital study and who
had no exclusionary medical or psychiatric condition
identified at the time of study (following section).
Because current classification of CFS was not completelyBMC Neurology 2006, 6:41 http://www.biomedcentral.com/1471-2377/6/41
Page 3 of 8
(page number not for citation purposes)
in accord with recruitment classification, strict matching
was not maintained, though cases and controls were
demographically comparable. Thirty-six (84%) of the 43
with CFS and 38 (88%) of the 43 controls were women;
most (40 CFS and 42 controls) were white; their mean
ages were 50.6 and 50.3 years, respectively; and body
mass index was 29.4 and 29.3, respectively.
Assessment and classification of CFS
Subjects who agreed to participate were admitted to a
Wichita hospital research unit for 2 days. Subjects brought
all their current medications so that clinic staff could
record this data and maintain medication profiles
throughout the study. To identify medical conditions
specified by the case definition as exclusionary for CFS
[1,11], participants provided a standardized past medical
history, a review of current medications, underwent a
standardized physical examination, and provided blood
and urine for routine analysis [1,11]. To identify psychiat-
ric conditions exclusionary for CFS, licensed and specifi-
cally trained psychiatric interviewers administered the
Diagnostic Interview Schedule for current Axis I disorders
[20]. Exclusionary psychiatric illnesses specified by the
case definition were current melancholic depression, cur-
rent and lifetime bipolar disorder or psychosis, substance
abuse within 2 years and eating disorders within 5 years.
A panel of physicians and psychiatrists/psychologists
reviewed this information and identified subjects with
disorders exclusionary for the diagnosis of CFS. Subjects
with no exclusionary conditions were considered to be
CFS if they met empirically measured parameters [19] of
the 1994 CFS case definition [1]. Non-fatigued controls
met none of the parameters.
Medication use
As noted, clinic staff reviewed all current (prescription and
over the counter) medications that study participants were
taking. Study investigators (DBR, MJD, CH, JFJ, WCR),
and other Emory University Department of Psychiatry and
Behavioral Sciences collaborators, reviewed all medica-
tions and classified them as affecting (inducing sleep,
inhibiting sleep or with mixed effects) or not affecting
sleep. Those classified as affecting sleep included analge-
sics (e.g., hydrocodone, Lortab, oxycodone, Propoxy-
phene), antidepressants (e.g., Celexa™, amitriptyline,
imipramine, Lexapro™, Wellbutrin™, Effexor, Prozac™,
Zoloft™, Paxil™, fluoxetine), antianxiety (Alprazolam),
antihistamines (e.g., diphenhydramine, chlorphen-
eramine, benadryl, promethazine), decongestants (e.g.,
pseudoephedrine, guaifenesen), anticonvulsants (e.g.,
Topamax, Neurotin, clonazepam), anti-sleep phase disor-
der (melatonin), blood pressure controlling (e.g., Cloni-
dine, Proamatine), antipsychotics (e.g., Seroquel,
Zyprexa, Fluvoxamine), stimulants (e.g., methylpheni-
date, Provigil), peristaltic stimulants (Metoclopramide),
and muscle relaxants (cyclobenzaprine). Medications
affecting sleep were handled as a binary measure (i.e., they
used or did not use one or more of those named above).
Analyses took into account use of sleep affecting medica-
tions, as noted below.
Polysomnographic and Multiple Sleep Latency Techniques
Nocturnal polysomnography and daytime multiple sleep
latency testing (MSLT) were conducted in a 4-bed labora-
tory established at Wesley Medical Center, Wichita, KS,
and consisted of polysomnography on night #1, MSLT the
following day and another polysomnography on night
#2. Patients were asked to arrive 3 hours before their typ-
ical bedtime on Night 1 to allow adequate time for elec-
trode application and standard biocalibrations. "Lights
out" and "lights on" time were 22:00 and 07:00, respec-
tively. The daytime MSLT testing schedule was adjusted
for other measures being collected; MSLT began at 11:00
and consisted of three additional naps at 13:00, 15:00,
and 17:00.
Electrophysiological measures of wakefulness and sleep
were acquired and recorded with the Flaga/Medcare
N7000 digital polysomnographic system on a Windows
XP platform using proprietary software (Flaga/Medcare
Somnologica Studio). We employed a sampling rate of
256 Hz to allow for Fast Fourier Transform of EEG signals.
Standard gold cup electrodes were employed for recording
of EEG, EOG, and EMG for sleep staging and appreciation
of sleep architecture. Respiration was measured with
inductance plethysmography-like belts placed around the
chest and abdomen. A pressure transducer, positioned in
close approximation to the nares provided indices of air-
flow. A pulse oximeter probe was applied to either the
right or left index finger, to measure arterial oxygen satu-
ration (Sa02). Electrocardiogram (ECG) was recorded
with standard snap electrodes (NeuroSupplies, Waterford,
CT). The following signals were recorded: central (C3-A2//
C4-A1) and occipital (O1-A1//O2-A2) EEG, left and right
monopolar EOG, surface mentalis EMG, ECG (modified
V3), respiratory airflow and effort and surface EMG from
the right and left anterior tibialis.
The polysomnographic outcome variables used in our
analyses included: total sleep time (TST) (in minutes),
sleep efficiency (% of time spent in bed asleep), the per-
centage of TST spent in non-Rem (NREM) and REM sleep,
sleep latency (in minutes) to three consecutive epochs of
sleep, and REM Latency, defined as the time between the
first epoch of any stage of sleep and the first epoch of
REM-sleep. Brief arousals were scored following criteria
set forth by the American Academy of Sleep Medicine, and
the number of arousals expressed as a rate per hour of
sleep adjusted for TST. Periodic leg movements both with
and without accompanying arousals, were scored accord-BMC Neurology 2006, 6:41 http://www.biomedcentral.com/1471-2377/6/41
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ing to conventional criteria [22], and expressed as an
index of the rate of leg movements per hour of sleep, and
a separately derived index of those accompanied by an
American Academy of Sleep Medicine -defined arousal
[23].
Daytime sleepiness was measured with the MSLT, which
has demonstrated objective sensitivity to the effects of
sleep deprivation, sleep fragmentation, sleep restriction,
insufficient sleep, hypersomnia, and in disease states such
as sleep apnea and narcolepsy [24-26]. Multiple sleep
latency tests were performed and scored according to
standard guidelines with the exception that four naps
were recorded at 11:00, 13:00, 15:00, and 17:00. The
mean sleep latency on the MSLT was defined as the mean
time from lights out to the first 30-second epoch scored as
sleep. A sleep onset REM was defined as one or more
epochs of REM sleep occurring within 15 minutes of the
first epoch scored as sleep. Mean MSLT values of 5 or less
are considered to represent pathological sleepiness, scores
between 5–10 are consistent with a degree of daytime
sleepiness. Scores of 10 and above are considered norma-
tive and believed to denote a lack of daytime sleepiness.
Because mean values on the MSLT may adversely be
affected by a spurious sleep latency on a single nap oppor-
tunity [27] possibly due to what might be perceived as
stressful inter-nap activities [28], median values were also
computed for each subject.
Interpretation of polysomnography data
Polysomnography data were scored by an Emory Univer-
sity registered polysomnology technologist (blinded as to
subjects' fatigue classification). An Emory University
Department of Neurology American Board of Sleep Med-
icine certified physician (DBR), also blinded to the sub-
jects' fatigue classifications, interpreted results. The
polysomnology technologist manually scored each
recording in 30 second epochs as wake, NREM, Stages 1–
4 sleep, or rapid eye movement (REM) sleep. Criteria for
scoring respiratory variables were based upon those of the
Sleep Heart Health Study [21]. Briefly, apnea was scored if
airflow decreased to less than or equal to 25% of the
immediately preceding baseline for a period of at least 10
seconds. Hypopnea was scored if either airflow or tho-
racic-abdominal excursion decreased by at least 30% of
baseline, for at least 10 seconds, with a concomitant
reduction in SaO2 of 4% or greater. The Respiratory Dis-
tress Index (apneas + hypopneas corrected for hour of
sleep) was derived from these scored events. To determine
the technologist's level of reproducibility, 12 randomly
selected studies were scored twice, with at least a six-week
interval separating the original scoring and the repeat
scoring. Comparison between original and repeat scorings
with Kappa analyses yielded a Kappa coefficient of 0.88.
Diagnostic criteria for sleep disorders exclusionary for CFS
The CFS case definition specifies sleep apnea and nar-
colepsy as conditions that could explain fatigue and
symptoms of CFS and therefore exclude the diagnosis of
CFS [1,11].
Obstructive sleep apnea
Obstructive sleep apnea was considered clinically signifi-
cant and therefore exclusionary if an individual's Respira-
tory Distress Index was ≥ 30 on either night, or was
between 10 and 30 and the individual had an abnormal
mean sleep latency of < 5 minutes during MSLT [29].
Narcolepsy
Narcolepsy was diagnosed if 2 out of 4 MSLTs were posi-
tive for REM sleep and mean sleep onset during MSLT was
< 5 minutes [29].
Statistical analysis
Data were analyzed by Systat (Systat Software Inc, Rich-
mond, CA) and SAS (SAS Institute Inc, Cary, NC). we used
A 2-factor analysis of variance using PROC GLM was to
measure the associations between case status and medica-
tion use (yes/no) with polysomnographic variables. Log
transformed values of polysomnographic variables were
used when necessary to satisfy the assumption of nor-
mally distributed outcomes. Mean values for each polys-
omnographic variable were adjusted for medication use
using the least square method (LSMEANS). All mean val-
ues presented in this paper represent arithmetic means.
We also used standard and exact logistic regression mod-
els to compute odds ratios as estimates of relative risks
and 95% confidence intervals for CFS associated with
dichotomous polysomnographic variables (cut-offs based
on 25th or 75th percentiles). Measurement of clinical sleep
variables included a high number of zero values. Zero-
inflated Poisson Regression was used to regress case status
and medication use (yes/no) on continuous values of
clinical sleep variables. For this final analysis, we used SAS
version 9.0 (PROC NLMIXED) and an inflation probabil-
ity determined by the regressors. Analyses were also per-
formed excluding participants taking medications that
affect sleep. Estimates were unchanged when analyses
excluded participants taking sleep-affecting medications.
For this reason, the results presented in this report do not
exclude participants taking such medications, but rather
adjust for them in the analysis. We used the χ2 statistic or
Fisher's exact test to evaluate associations between CFS
and dichotomous variables.
Results
Primary sleep disorders
Eleven study participants had sleep disorders exclusionary
for CFS (obstructive apnea n = 8, narcolepsy n = 3). Per-
sons with CFS had a higher frequency of exclusionaryBMC Neurology 2006, 6:41 http://www.biomedcentral.com/1471-2377/6/41
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sleep disorders (8 of 43, 18.6%) than non-fatigued con-
trols (3 of 43, 7%), but the difference was not statistically
significant (p = .16). The remainder of this presentation
considered the remaining 35 individuals with CFS and 40
controls.
Sleep architecture and MSLT
There were no statistically significant differences in stand-
ard polysomnographic measurements between those with
CFS and controls on either night 1 or night 2. As expected,
total sleep time increased in both groups between nights
1 and 2; latency to sleep onset and to REM onset decreased
in both groups; and, waking after sleep onset was less
common in both groups on night 2 (data not shown). As
night 1 was considered to be an adaptation night, data is
shown for night 2 (Table 1). Mean values, adjusted for
medication use, did not differ between participants with
CFS and non-fatigued controls. Interestingly, regardless of
case status, medication use was independently associated
with both REM latency and Stage 1 % total sleep time.
Both REM latency and Stage-1 percent of total sleep time
were significantly longer in study participants who
reported using any sleep medications at the time of the
study (P = .02, P = .01, respectively). In addition to com-
paring polysomnographic measurements as continuous
variables between people with CFS and non-fatigued con-
trols, we used regular and exact logistic regression to
examine possible associations. We dichotomized meas-
urements based on 25th and 75th percentiles among non-
fatigued controls. As with the previous analyses there were
no significant differences (data not shown). Virtually
identical results were obtained when analysis was
restricted to subjects who did not use sleep-altering medi-
cations. Finally, evaluation of multiple sleep latency test-
ing studies yielded similar distributions of classifications;
(39% normal, 35% borderline and 26% abnormal)
between CFS and controls.
Disordered breathing and periodic leg movements during 
sleep
Subjects with CFS had significantly more episodes of
obstructive apnea and a higher Respiratory Distress Index
than did the non-fatigued controls (Table 2). Nonethe-
less, the difference between the groups in mean obstruc-
tive episodes per hour of total sleep was not of a
magnitude recognized to have a clinical impact. All other
measures of disordered breathing and periodic leg move-
ments were not different between the two groups. Use of
medications affecting sleep was independently associated
with a higher rate of hypopnea and leg movements epi-
sodes per hour, after adjusting for case status (P = .03, P =
.05, respectively). However, use of sleep altering medica-
tion was associated with a lower rate of obstructive apneic
episodes per hour (P <.0001).
Discussion
To our knowledge, this represents the most comprehen-
sive polysomnographic analyses of a community sample
of rigorously evaluated people with CFS and frequency-
matched non-fatigued controls. There were no significant
differences in rates of primary sleep disorders between
CFS cases and NF controls. Thus, in spite of additional
attention to methodological issues, our findings are in
agreement with prior studies of CFS patients identified
through clinical referral [6,12-16]. Similarly, there were
no differences in any measured sleep parameters, with the
exception of the frequency of obstructive apnea per hour
of nighttime sleep and these differences were not clini-
cally meaningful. While subtle breathing problems during
sleep might plausibly contribute to CFS, the most striking
finding of this study in fact is the absence of readily identi-
fiable differences in objective, polysomnographically
defined, sleep parameters between subjects with CFS and
non-fatigued controls. Similarly, there were no differences
between persons with CFS and non-fatigued controls with
respect to daytime multiple sleep latency tests. The lack of
differences in overnight sleep parameters and MSLT is in
contrast to the participants' self-reported symptoms. For
example, 97% of persons with CFS in this study reported
unrefreshing sleep compared with 20% of controls. As
noted by others, persons with CFS may suffer from an ele-
ment of sleep-state misperception [30]. Future studies
should further scrutinize the association between subjec-
tive sleep quality and objective polysomnographic results
in persons with CFS.
Disorders of sleep were common in both CFS cases and
controls in this study. Indeed primary sleep disorders that
may respond to therapy were identified in 13% of the
overall study population. These findings were unexpected;
as the population-based nature of the study eliminated
referral bias and potential participants were excluded
from the study of they reported diagnosed narcolepsy or
sleep apnea disorders during screening interviews.
Despite this, sleep apnea and narcolepsy of clinically sig-
nificant severity were identified in 11 participants, requir-
ing their exclusion from the study. As participants with
sleep disorders were not identified until polysomno-
graphic studies were performed, it is arguable that in clin-
ical situations, referral of subjects with unexplained
fatigue to a sleep laboratory should be considered in an
effort to identify disorders that may respond to interven-
tion. In research settings case ascertainment does not usu-
ally include formal sleep studies. Thus, the potential
impact of including subjects with primary sleep disorders
in the CFS diagnosis should be considered when interpret-
ing results from such studies, and when designing CFS
studies. Finally, MSLTs were borderline or abnormal in
60% of subjects. This may be attributed to the occurrence
of sleep disorders in our study population, or to environ-BMC Neurology 2006, 6:41 http://www.biomedcentral.com/1471-2377/6/41
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mentally induced sleep disruption occurring during the
night preceding the MSLT.
The study has several weaknesses that should be consid-
ered while evaluating the results. While one of the largest
studies identifying CFS cases and NF controls from the
general population to date, the small numbers of identi-
fied subjects with current CFS may not be sufficient to
identify small but biologically significant differences in
sleep architecture. Second, our subjects spent two nights
in the sleep lab (to allow accommodation) and (although
adequate to detect primary sleep disorders) this may not
Table 1: Analysis of Sleep Architecture in CFS and Controls, Measured on Night 2 and Adjusted for Medication Use
CFS NF
n = 35 n = 40
Adjusted Mean* Adjusted Mean* P-Value**
Total sleep time (min) 400.3 407.9 0.52
Sleep period time (min) 453.8 457.8 0.79
Latency to sleep onset (min) 21.3 17.1 0.47
REM latency (min) 98.4 106.8 0.40
Sleep efficiency (%) 88.3 90.2 0.32
Wake after onset (min) 53.8 44.0 0.69
Wake % Sleep Period 11.7 9.8 0.72
# Arousals 105.7 110.2 0.81
Arousal index 15.9 16.3 0.82
Stage 1 (% TST) 9.6 9.5 0.79
Stage 2 (% TST) 48.2 50.8 0.28
Stage 3/4 (% TST) 19.9 17.4 0.20
REM (% TST) 22.3 23.3 0.98
* Mean values adjusted for medication use (yes/no)
** P-values generated using 2-factor analysis of variance
Table 2: Distribution of Breathing and Movement Abnormalities During Sleep
Clinical Sleep Variable CFS (n = 35) NF (n = 40) P-value*
Hypopnea
Mean event/hr 2.66 1.79 P = 0.24
Range (0.00 – 16.03) (0.00 – 14.66)
Obstructive Apnea
Mean event/hr 0.94 0.59 P = 0.003
Range (0.00 – 12.11) (0.00 – 10.70)
Central Apnea
Mean event/hr 0.36 0.15 P = 0.18
Range (0.00 – 2.44) (0.00 – 1.89)
Mixed Apnea
Mean event/hr 0.14 0.15 P = 0.58
Range (0.00 – 2.28) (0.00 – 3.15)
Snore Index
Mean 5.31 4.57 P = 0.95
Range (0.00 – 27.50) (0.00 – 34.30)
Respiratory Distress Index
Mean 4.11 2.69 P = 0.009
Range (0.10 – 21.21) (0.00 – 20.35)
Periodic Leg Movements
Mean events/hr 4.42 4.56 P = 0.35
Range (0.00 – 25.74) (0.00 – 39.37)
Periodic Leg Movements with Arousals
Mean events/hr 1.03 0.87 P = 0.62
Range (0.00 – 11.57) (0.00 = 7.09)
*P-values were generated using zero-inflated Poisson regression, adjusting for use (yes/no) of sleep medications. Mean values represent arithmetic 
means. Leg movement was not measured in 9 CFS cases and 1 control.BMC Neurology 2006, 6:41 http://www.biomedcentral.com/1471-2377/6/41
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produce an accurate picture of subtle nocturnal sleep
behaviors. Moreover, sleep-altering medications were fre-
quently used by both CFS cases and controls and their use
was much more common among CFS cases. Some of these
medications have opposite effects on sleep and we chose
to lump them a sleep-altering. While we employed statis-
tical corrections for their use, may have been inadequate
to fully correct for the varied impact of the different for-
mulations. It should nonetheless be noted that stratified
analyses restricted to those without sleep-altering medica-
tions yielded similar findings compared to the total sam-
ple, although the greatly reduced numbers further limited
the power of the examination. Finally, the median dura-
tion of CFS in the Wichita population was 7.3 years [4];
thus, findings in this study of prevalent cases may not be
applicable to those with shorter illness duration.
Conclusion
In conclusion, although this study evaluating associations
between sleep physiology and CFS addressed the major
limitations and methodological issues of previous studies,
we could not confirm statistically significant associations
between sleep parameters and CFS. Sleep abnormalities
therefore are an unlikely contributor to the pathophysiol-
ogy of CFS and the illness may include sleep-state misper-
ception. However, 18% of persons with CFS had
previously unrecognized clinically severe apnea or nar-
colepsy, demonstrating the importance of evaluating per-
sons with otherwise unexplainable chronic fatigue for
sleep disorders. Additional, sufficiently powered, studies
with CFS cases identified from the population should be
conducted.
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